Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy

J Am Acad Dermatol. 2016 Nov;75(5):1054-1057. doi: 10.1016/j.jaad.2016.06.062.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Antigens, CD19
  • Blood Transfusion, Autologous / adverse effects*
  • CD3 Complex / genetics
  • CD3 Complex / immunology
  • Cytokines / metabolism
  • Hematologic Neoplasms / therapy
  • Humans
  • Immunotherapy / adverse effects*
  • Immunotherapy / methods
  • Lymphocyte Transfusion / adverse effects*
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / etiology
  • Neoplasms, Second Primary / immunology
  • Protein Domains
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Skin Diseases / diagnosis
  • Skin Diseases / etiology*
  • Skin Diseases / immunology
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / etiology
  • Skin Neoplasms / immunology
  • Syndrome
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Cytotoxic / transplantation*
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / genetics
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / immunology

Substances

  • Antigens, CD19
  • CD19 molecule, human
  • CD3 Complex
  • CD3 antigen, zeta chain
  • Cytokines
  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins
  • TNFRSF9 protein, human
  • Tumor Necrosis Factor Receptor Superfamily, Member 9